Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a provider of vascular devices, implants, and services for the treatment of peripheral vascular disease, with products developed for use by vascular surgeons. This news page aggregates company announcements, earnings releases, and other disclosures so readers can follow how LeMaitre’s vascular device business evolves over time.
In its regular quarterly updates, LeMaitre reports on net sales, gross margin, operating income, earnings per share, and geographic sales across the Americas, EMEA, and Asia Pacific. These releases often highlight which product categories, such as grafts, shunts, and catheters, are driving growth, and may call out specific products like the Artegraft biologic graft used in AV access and peripheral bypass. The company also discusses organic sales growth, adjusted profitability metrics, and the impact of pricing, volume, and manufacturing efficiencies.
Beyond earnings, LeMaitre issues news about dividends, share repurchase authorizations, and participation in healthcare and investor conferences hosted by firms such as Bank of America Securities, Wells Fargo, Morgan Stanley, and others. These events provide additional context on the company’s strategy, international expansion, and regulatory milestones, including launches of products like Artegraft in new markets.
Investors and observers can use this page to review historical press releases, monitor guidance updates, and see how management characterizes risks and opportunities in the peripheral vascular disease market. For ongoing coverage of LMAT news, this feed offers a centralized view of the company’s public communications and financial reporting.
LeMaitre Vascular (Nasdaq:LMAT) announced that CFO JJ Pellegrino will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 12:00 PM ET in Boston. The company focuses on devices, implants, and services for treating peripheral vascular disease, affecting over 200 million people globally. LeMaitre develops and markets vascular devices aimed at the needs of vascular surgeons. For more details, visit lemaitre.com.
LeMaitre (LMAT) reported Q2 2022 sales of $42.1 million, up 4% year-over-year. Gross margin increased to 66.0%. However, operating income fell 48% to $5.8 million, and EPS declined by 60% to $0.16. The company announced a quarterly dividend of $0.125/share and increased guidance for 2022 to 10% organic growth. Key growth drivers included biologics, especially XenoSure (+21%).
The company closed its St. Etienne factory, incurring a $3.1 million special charge.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q2 2022 financial results on July 28, 2022, after market close. The company has scheduled a conference call at 5:00 PM ET the same day to discuss the results, business highlights, and future outlook. LeMaitre specializes in developing and marketing devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that its President, David Roberts, will present at the Sidoti Summer Small Cap Virtual Conference on June 15, 2022, at 2:30 PM ET. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million individuals globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. For additional information, visit www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in two investor conferences in May and June 2022. CFO JJ Pellegrino is set to present at the UBS Global Healthcare Conference on May 23 at 2:00 PM ET in New York City. Additionally, President David Roberts will present at the Jefferies Healthcare Conference on June 8 at 9:30 AM ET, also in New York City. LeMaitre is a key provider of devices and services for treating peripheral vascular disease, affecting over 200 million people globally.
LeMaitre (NASDAQ: LMAT) reported its Q1 2022 results, highlighting a sales increase of $39.6 million, up 10% year-over-year. Operating income remained flat at $7.9 million with a 20% operating margin. The company announced a quarterly dividend of $0.125 per share and provided updated guidance for 2022, forecasting sales of $160-$164 million. Key developments included a buyout of its Korean distributor and the closure of its St. Etienne factory, expected to reduce future operating costs. However, the strong U.S. dollar negatively impacted both sales and operating income guidance.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q1 2022 financial results on April 28, 2022, post-market. A conference call is scheduled for 5:00 PM ET to discuss the results and company outlook. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company develops and markets both disposable and implantable vascular devices targeted at vascular surgeons. Further details can be found at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that Chief Financial Officer JJ Pellegrino will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 10:15 AM ET. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company focuses on developing disposable and implantable vascular devices tailored for vascular surgeons.
LeMaitre (Nasdaq:LMAT) has been added to the NASDAQ US Broad Dividend Achievers Index, recognizing companies with a decade of increasing dividends. Since initiating dividends in 2011, LeMaitre's payout per share rose from $0.08 to $0.44 in 2021, achieving an 18.6% compounded annual growth rate. A new quarterly dividend of $0.125 will be distributed on March 24, 2022. CEO George W. LeMaitre emphasized the company's commitment to profitability and an improved balance sheet through consistent dividend increases.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four significant investor conferences this March. The 34th Annual Roth Conference is scheduled for March 14, 2022, with President David Roberts presenting. Following that, the Oppenheimer 32nd Annual Healthcare Conference takes place on March 16, 2022, featuring CFO JJ Pellegrino. On March 17, 2022, Roberts will present at the Barclays Global Healthcare Conference, and the month concludes with the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022.
FAQ
What is the current stock price of Lemaitre Vasculr (LMAT)?
What is the market cap of Lemaitre Vasculr (LMAT)?
